Forty-four patients with chronic low back pain were randomized to receive either Botulinum toxin type A (BoNT-A; n=22) or a placebo (n=22). The primary outcome was the reduction in pain, measured by the Visual Analog Scale (VAS). Secondary outcomes included disability assessed by the Oswestry Disability Index (ODI) and the safety of the intervention. Outcomes were evaluated at baseline and after 8 weeks. Overall, both groups experienced significant reductions in VAS and ODI scores. However, the reduction in ODI scores was statistically significant but clinically insignificant, and changes in VAS scores were not statistically significant. The study concluded that BoNT-A did not provide a short-term advantage over placebo for pain relief or functional improvement in chronic low back pain.